There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Option Care Health (OPCH – Research Report) and Crispr Therapeutics AG (CRSP – Research Report) with bullish sentiments.
Option Care Health (OPCH)
In a report released yesterday, Joanna Gajuk from Bank of America Securities reiterated a Buy rating on Option Care Health, with a price target of $43.00. The company’s shares closed last Monday at $30.26.
According to TipRanks.com, Gajuk is a 1-star analyst with an average return of
Option Care Health has an analyst consensus of Strong Buy, with a price target consensus of $39.20.
See the top stocks recommended by analysts >>
Crispr Therapeutics AG (CRSP)
In a report released today, Tim Lugo from William Blair maintained a Buy rating on Crispr Therapeutics AG. The company’s shares closed last Monday at $71.51, close to its 52-week high of $76.19.
According to TipRanks.com, Lugo is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $85.25 average price target, representing a 23.4% upside. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $74.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OPCH:
- Third Point buys T-Mobile, boosts Microsoft in Q3
- Option Care Health price target lowered to $35 from $41 at Barrington
- Option Care Health price target lowered to $35 from $39 at Deutsche Bank
- Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2023
- Option Care Health sees 2023 revenue $4.23B-$4.28B, consensus $4.28B
